Icon

TECFIDERA (nda204063)- (120MG,240MG)

DIMETHYL FUMARATE BIOGEN INC
120MG,240MG
Yes No
2035-Nov-16 2018-Mar-27
None None
None No
TECFIDERA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
15 3 13
Total Other Developers 6
Drugs with Suitability No
120MG ** ** - - -
240MG ** ** Down 10 1
NDA Sales Available Total Generic Sales Available
Yes 9
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** *** ******** ******* ******* *** *********** **. **. ***/*, ********* (*******), *********(******), ******* *********** ********, ********* ******, ***** (***) ***
****** ***** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** **. *, *****-*, ****** **** *** *********, ****, ****** ******* ******, ***** (***) ***
****** *** ****** *** ***************, ***. ******* ***** *********** *-*, ******* *** **., ******* ****, ******, ****** (***) ***
****** *** ****** *** ***************, ***. ******* ***** ******** ** *********** **, ******** **.,, ******* ****, ******, ****** (***) ***
****** ****** ****** *************** ******* ******* *********** ****** **.***, *** ** ***, **** ***** ********* *******-***** *******, ******* ******, *** *****, *********, ******* ******, ***** (***) ***
****** ***** **** *** ***** ************ ******* *********** ****** ** ****, ****, ****, **** ******* *****, ****** ********, *****, ******** ******* ******, ***** (***) ***
****** *** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ****** **** *** *** ****** **** ******* *********** **** ***, **** **. **-***, ****-**, ***, **********, *********, ********* ******, ***** (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** ********* ****** ******** ****** ******* ******* *** *********** ****-**, **.**'*.**,**,**,**,** ** **,***&***, ************** * & **.** *,*,****,**,**,**,**&**, ************ *, *********** ******, **********, ****** ******* ******, ***** (***) ***
****** ********* ****** *** ********** ******* *********** ****-**, **** **.**, *****, *.*.***, ******** *******, ********* ******, ******** ********, ********, ****** ******* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** ******* *****, **** ****** **********,****** *****, ******** *****, ******** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.